Cuban scientists to present results of clinical trials of new drug

HAVANA, Cuba (ACN) — Experts from different branches of medicine in Cuba were on Thursday due to present the latest results of the application of Hebervital, a product of the Cuban biotechnology sector, in a national workshop in Havana.

Hematologists, oncologists, orthopedists, dentists, intensive care specialists and others met to announce the advantages and new clinical research of this product that is used in Cuba’s national health system with notable benefits in different pathological processes, said Iris Lugo, communication specialist of the Genetics Engineering and Biotechnology Center (CIGB by its Spanish acronym).

Developed by the CIGB, Hebervital is used in patients receiving chemotherapy, radiation therapy, bone marrow transplants and immune-depressed persons, experts say.

It is also applied to patients with decreased body defences and with a history of severe or recurrent infections, and its benefits includes reduction of antibiotic use and frequency of hospitalization.

The timely use of this drug allows completing the chemotherapy and radiation therapy regimen in cancer patients, which provides better treatment effectiveness and quality of life.

According to experts, Hebervital is a first-line stimulant factor in supporting cancer therapy because it increases the number of stem cells, which are subsequently collected to be infiltrated.

It has shown effectiveness in hepatic cirrhosis, peripheral arterial insufficiency, pathologies of the knee and hip joints, as well as in skin lesions, alopecia and scars due to juvenile acne, among other ailments.

At the first national meeting on the extension of the use of Hebervital, Dr Porfirio Hernández, an expert from the Institute of Hematology and Immunology, highlighted the advantages of this drug that has been used for 15 years in medical practice, with very good results, mainly in oncology and hematology.(Caribbean News Now)

About the author

Leave a Comment

Security Question * Time limit is exhausted. Please reload CAPTCHA.

Powered by WordPress